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Jin Zhu1,2†, Yingmei Wang1†, Li Gong3 and Gaosheng Huang1*Abstract
Background: Primary pulmonary lymphoma (PPL) is rare and easily misdiagnosed because of the lack of typical
clinical features. It most commonly involves elderly patients aged between 60 and 70 years, and pathological
diagnosis depends mainly on chest surgery rather than bronchial mucosal biopsy. Via percutaneous needle
aspiration biopsy of the lung of a 33-year-old woman, which had distinct tissue eosinophilia, we diagnosed a rare
case of rapidly growing large B cell lymphoma.
Methods: Bronchial mucosal biopsy and computed tomography–guided percutaneous needle aspiration biopsy
were performed to determine the nature of the lesion, and we identified its immunophenotype using
immunohistochemistry. We used BIOMED-2 gene rearrangement PCR to determine lymphocyte clonality; laser
microdissection was used to confirm the clonality of suspicious malignant lymphocytes.
Results: Morphologically, the lesion was composed of a large number of eosinophilic cells and a few lymphoid
cells. Immunohistochemical staining revealed a few CD1α-positive cells, but they were S-100–negative. The small
lymphoid cells predominantly expressed CD3; the large lymphoid cells expressed CD20 and some scattered large
lymphoid cells expressed Pax5. However, molecular studies confirmed clonal immunoglobulin heavy chain (IGH)-D
gene rearrangement in Pax5–positive large B lymphocytes.
Conclusions: This is the first recorded case of T- cell/histiocyte-rich large B cell lymphoma with tissue eosinophilia
of the lung. It highlights the unusual morphological features of PPL that might be mistaken for eosinophilic granuloma
or parasitic infection. In addition, IGH and T cell receptor gene rearrangement play important roles in differentiating rare
B cell lymphoma from lung space–occupying lesions with abundant eosinophils or T cell infiltration.
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Primary pulmonary lymphoma (PPL) is defined as a clonal
lymphoid proliferation affecting one or both lungs in a
patient with no detectable extrapulmonary involvement at
diagnosis. It is a rare entity, representing less than 1%
of primary pulmonary malignancies and accounting for
4–11% of extranodal lymphomas [1-3]. Due to its atypical
clinical manifestation and complicated imaging features,
PPL is easily misdiagnosed and incorrectly treated.
Historically, PPL diagnosis mainly depends on chest
surgery to obtain pathological evidence, and most cases
cannot be diagnosed only by bronchial mucosal biopsy
[4,5]. We describe a case of primary pulmonary large B cell
lymphoma with marked tissue eosinophilia and increased
T cells in which histological, immunohistochemical, and
gene rearrangement findings were combined to obtain a
diagnosis by computed tomography (CT)-guided percu-
taneous needle aspiration biopsy.
Case presentation
Clinical history
A 33-year-old woman had cough and expectoration
without fever or other discomfort. A peripheral blood
count revealed an increased white cell count, but there
was no obvious abnormal change on chest radiographs.
Thus, the local physician attributed her symptoms to
allergic bronchitis and she received anti-inflammatory
treatment. However, she visited the hospital again after
five months because of the same symptoms, which were
accompanied by severe shortness of breath. Laboratory
examination revealed increased white blood cells in the
peripheral blood, but the absolute value of eosinophilic
granulocytes was in the normal range. Other tests showed
increased erythrocyte sedimentation rate (ESR), negative
autoantibody, carcinoembryonic antigen far lower than the
reference value, but a weakly positive Postscript Printer
Description skin test. Chest radiography and CT scan
revealed a space-occupying lesion in the upper lobe of
the right lung, which indicated lung cancer with atelec-
tasis of the right upper lung (Figure 1) without nodal
involvement. We performed bronchial mucosal biopsy
and CT-guided percutaneous needle aspiration biopsy
(aspiration biopsy), which revealed extensive eosinophil
infiltration and no evidence of malignancy. Positron
emission tomography scan and bone marrow biopsy were
also normal. Repeated sputum cultures and parasite antigen
testing excluded bacterial and parasitic infection, respect-
ively. In addition, we did not find acid-fast bacilli from
smears or bronchoalveolar lavage fluid (BALF), and the
Mycobacterium tuberculosis (TB) DNA copy number from
the BALF and lung biopsy tissues were all <25 copies/mL;
therefore, we also excluded TB. The lesion was suspected
eosinophilic granuloma, and the patient received an experi-
mental glucocorticoid treatment that successfully alleviatedher symptoms. However, subsequent CT scans revealed
an increased mass, and the patient underwent biopsy




Immunohistochemical staining was performed using
EnVision™ Systems (Dako, Glostrup, Denmark) according
to the manufacturer’s instructions. The primary antibodies
used were mouse anti-human antibodies against anaplastic
lymphoma kinase (ALK), clusterin, CD34, AE1/AE3, CD30,
CD1α, CD20, and CD68, and rabbit anti-human anti-
bodies against S-100, CD3, and Pax5. All reagents were
supplied by Dako but CD3 and CD34 was from Maixin
Biotechnology Corp. Ltd. (Fuzhou, China).
Laser microdissection
Ten 10-μm tissue sections (1.5 × 1.5 cm2) were obtained
from representative paraffin blocks and placed on an
ultraviolet (UV)-absorbing membrane. The sections
underwent laser microdissection using an LMD6000
laser microdissection microscope (Leica Microsystems Ltd.,
Wetzlar, Germany). After immunohistochemical staining,
slides were mounted on a microstat, and Pax5–positive
lymphoid cells were dissected using a UV laser in mo-
torized optical beam scanning mode. The membrane
(with the attached specimen) was dropped into the cap
of a 0.5-mL microcentrifuge tube and prepared for
DNA extraction. For each dissected lesion, a similar
volume of surrounding normal lung tissue was isolated
and analyzed as a control.
DNA extraction
Four 20-μm thick sections from formalin-fixed, paraffin-
embedded (FFPE) tissue blocks obtained by aspiration
biopsy were cut into centrifuge tubes. We isolated DNA
from microdissection samples or aspiration biopsy samples
using the RecoverAll™ Kit (AM1975; Ambion, Foster City,
CA, USA) according to the manufacturer’s protocol. Briefly,
FFPE tissue samples were deparaffinized with xylene and
graded ethanol and then digested with the appropriate vol-
ume of lysate buffer (40 μL for microdissection samples;
100 μL for aspiration biopsy samples) and proteinase K
(2 μL for microdissection samples; 6 μL for aspiration
biopsy samples) in a water bath (50 °C) for 16 h. We added
the appropriate volume of isolation additive/ethanol mix-
ture to each sample and filtered or washed them repeatedly.
After RNase digestion and DNA purification, the genomic
DNA was extracted and stored at −20°C.
BIOMED-2 gene rearrangement analysis
We evaluated the clonality of T cell receptor (TCR) and
immunoglobulin heavy chain (IGH) genes using the PCR
Figure 1 Chest radiograph and lung CT scan. A: Chest radiograph showing widened mediastinum in the upper-middle lobe and upper lobe atelectasis
in the right lung, indicating a space-occupying lesion. B: Lung CT scan showing a right hilar mass measuring about 5.0 × 4.8 cm (arrow).
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conditions were selected for a final volume of 50 μL
containing 100 ng DNA, 200 μM dNTP, 10 pmol each
primer irrespective of total numbers of primers in each
multiplex PCR tube, 1.5 mM MgCl2, and 1 U Taq enzyme.
Amplification was performed using an Eppendorf
thermal cycler (Eppendorf, Hamburg, Germany) for
35 cycles (denaturation at 94°C for 1 min, annealing
at 60°C for 1 min, extension at 72°C for 1 min). The
PCR products were visualized using polyacrylamide
gel electrophoresis.Figure 2 Histopathological characteristics of the lesion. A, B: Hematox
eosinophilia in the lesion (Figure 2A, ×100; Figure 2B, ×400). C, D: H&E-stain
few eosinophils (Figure 2C, ×200; Figure 2D, ×400).Results
Pathological observation
At the first aspiration biopsy, histopathology revealed
numerous eosinophilic cells infiltrating the lesion
(Figure 2A-B), and no definite tumor cells were found.
Immunohistochemical staining was negative for S-100,
ALK, clusterin, CD34, AE1/AE3; there were only a few
large CD30-positive and CD1α-positive cells (Figure 3A),
but more CD68-positive cells (Figure 3B).
Following glucocorticoid treatment, histopathology
revealed focal accumulation of lymphocytes and lessylin–eosin (H&E)-stained aspiration biopsy section showing marked
ed aspiration biopsy after glucocorticoid treatment showing only a
Figure 3 Immunohistochemical features of the lesion. A: Immunohistochemical CD1α staining showing only a few CD1α-positive cells (×400).
B: Immunohistochemical CD68 staining revealing a diffused pattern of CD68-positive cells (×400). C: Immunohistochemical CD3 staining revealing
a predominant nodular pattern of CD3-positive cells (×400). D: Immunohistochemical CD20 staining revealed that many large lymphoid cells were
positive. E: Immunohistochemical Pax5 staining showing scattered, Pax5–positive large B cells (×400).
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staining showed that the background small lymphocytes
predominantly expressed CD3 (Figure 3C), while many
large lymphoid cells strongly expressed CD20 (Figure 3D)
and some large lymphocytes expressed Pax5 (Figure 3E),
and their average nuclei diameter was approximately
11 μm. The distribution of Ki67-positive cells was not
even, but most of the cells were scattered larger cells.
Gene rearrangement
Gene rearrangement analysis of the lung biopsy tissue
revealed rearrangement of clonal IGH genes, including
IGH-D and IG kappa (K)-B, and no clonal rearrangement
of TCR genes (Figure 4). Laser capture microdissection
determined that the IGH-D gene rearrangement (Figure 5)
mainly occurred in Pax5–positive large B lymphocytes.Diagnosis and outcome
Based on the histopathological characteristics, immunohis-
tochemical features, and gene rearrangement analysis, we
eventually diagnosed the patient with primary pulmonary
T- cell/histiocyte-rich large B cell lymphoma with tissue
eosinophilia. Subsequently, she completed three cycles
of chemotherapy dominated by the cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) or
CHOP-like regimen. CT scan performed at the last follow-
up revealed a significantly reduced mass.
Discussion
PPL is very rare, and its biological features, clinical
presentation, prognostic markers, and treatment are
not well defined. Although PPL has various clinical
symptoms, they are nonspecific and contribute little to
Figure 4 Results of gene rearrangement analysis of aspiration biopsy tissue. A: IGH gene rearrangement analysis revealing rearrangement
of clonal genes, including IGH-D (arrow) and IGK-B (arrow). Lane 1: IGH-A; lane 2: IGH-B; lane 3: IGH-C; lane 4: IGH-D; lane 5: IGH-E; lane 6: 50-bp
marker; lane 7: IGK-A; lane 8: IGK-B; lane 9: IG lambda (L); lane 10: internal control. B: TCR gene rearrangement showing no band and no evidence
of clonal gene rearrangement. Lane 1: TCR-gamma(G)A; lane 2: TCR-GB; lane 3: TCR-delta(D); lane 4: 50-bp marker; lane 5: TCR-beta(B)A; lane 6:
TCR-BB; lane 7: TCR-BC; lane 8: positive control; lane 9: negative control; lane 10: blank control.
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asymptomatic [2,7]. Moreover, the rate of constitutional
symptoms and acute-phase reactants (sedimentation,
C-reactive protein) are high in patients with PPL,
which is also not specific to the diagnosis [8]. Thus, in
addition to the pathological manifestations of bronchial
mucosal biopsy and surgical biopsy, abnormal chest radi-
ography and CT images may also be of value for diagnosis.
Recently, increased numbers of disuse large B-cell lymph-
oma (DLBCL) cases with various manifestations have been
reported, which could be misdiagnosed as TB [9] or lung
cancer [10]. A long-term follow-up study of PPL-DLBCL,
the largest known series thus far, noted strong homogen-
eity among the patients: low clinical risk, early stage,
and no bulky tumor mass, normal lactic dehydrogenase
and beta 2 microglobulin [11]. Yet, some cases also have
unusual morphological features, where primary pulmon-
ary B cell lymphoma might present as a necrotic mass or
mediastinal type [12,13].
The most common histopathological subtypes of PPL are
mucosa-associated lymphoid tissue (MALT) lymphoma
and diffuse large B cell lymphoma (DLBCL), which occurs
only in 10% of cases [14,15]. In general, there is no clear
classification of DLBCL encountered in pulmonary systems.
In fact, PLL-DLBCL has been reported only in case reports
[9,10], most subtypes of them are centroblastic or immuno-
blastic variants, as elsewhere, which are the more common
morphological variants of DLBCL [1,11,16,17]. In addition,
some rare types of DLBCL, such as the anaplastic variant,
were also reported [18]. Histopathologically, the case we
presented here contained both large and small lymphoid
cells, and abundant eosinophils were also found in thetumor tissue. Immunohistochemical staining revealed that
the large lymphoid cells were B-cells (both CD20- and
Pax5-positive) and small lymphoid cells were predom-
inantly T-cells (CD3-positive) in nature. Our finding is
obviously different from the studies [11,13,19] in which
immunophenotype of primary B cell lymphoma of the
lung is commonly CD3-negative. Meanwhile, many CD68-
positive cells were also found, but there were only a few
large CD30-positive and CD1α-positive cells in the tumor
tissue. In addition, no any S100-positive and definite CD15-
positive cells were found. It means that large B-cells are
mingled with abundant small T-cells and histiocytes.
BIOMED-2 gene rearrangement analysis [6] of both the
lung tissue and tumor cells confirmed that large B-cells
are neoplastic and small T-cells are reactive. Therefore,
the diagnosis of this case is T- cell/histiocyte-rich large
B cell lymphoma (THRLBCL), which is a special and
rare subtype of DLBCL. Based on the typical cellular
and immunohistochemical features of THRLBCL, which
is composed of the dispersed large B-cells, predominant
small T-cells and more histiocytes, it is not difficult to dif-
ferentially diagnose it from other large B-cell lymphoma.
If there is a difficult case, laboratory evaluation for EBV
[20,21] and immunohistochemical staining of OCT2 and
BOB1 [22,23] may be useful for the differential diagnosis
of THRLBCL with other large B-cell lymphoma.
Upon histopathological examination, a marked increase
of eosinophils in non-blood tissue could be diagnosed
as tissue eosinophilia. However, eosinophilia refers to
increased eosinophils (>0.45 × 109/L) in the peripheral
blood [24]. Peripheral blood and tissue eosinophilia
may occur in many disorders, including allergic and
Figure 5 Results of gene rearrangement analysis of microdissection
tissue. Laser capture microdissection of Pax5–positive large B lym-
phocytes confirm clonal IGH-D (arrow) gene rearrangement. Lane 1:
IGH-D; lane 2: IGK-B; lane 3: 50-bp marker; lane 4: internal control.
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atopic reactions, immune complex disorders, connective
tissue diseases, and malignant tumors. Both solid tu-
mors and hematopoietic neoplasms are associated with
eosinophilia. Eosinophilia and tissue eosinophilia are
frequent findings in Hodgkin lymphoma [25] and are
sometimes observed in patients with lymphoma, predomin-
antly T cell lymphoma or occasionally anaplastic large cell
lymphoma [26,27]. Historically, large B cell lymphoma
with marked eosinophilia is rare, and only a few cases of
mediastinal/thymic large B cell lymphoma may present
a few reactive infiltrating lymphocytes and eosinophils.
Its clinical manifestation is an anterior mediastinalspace-occupying lesion, usually accompanied by super-
ior vena cava syndrome, and is easily misdiagnosed as
Hodgkin lymphoma. To date, there are only a few reports
on eosinophilia or tissue eosinophilia in B cell lymphoma,
and all biopsy samples are obtained from lymph nodes
[28-30]. In our case, however, it was primary pulmonary
B cell lymphoma without evidence of nodal involvement,
and all biopsy samples were obtained from lung tissue.
The peripheral blood eosinophilic granulocyte count was
in the normal range, and the bone marrow biopsy was
normal. These findings did not support the diagnosis of
eosinophilia. However, histopathological examination
disclosed a lesion with marked eosinophil infiltration,
some of which formed eosinophilic abscesses.
The differential diagnoses of eosinophil-rich lesions
of the lung included eosinophilic granuloma, Hodgkin’s
lymphoma and parasitic or viral infections. In eosinophilic
granuloma, there are a large number of characteristic
Langerhans cells, which have typical nuclear grooves
and showed both CD1α and S100 diffuse positive staining.
Furthermore, the gene rearrangement analysis can not
reveal the clonal rearrangement of IGH genes. In classical
Hodgkin’s lymphoma, there are the typical Reed-Sternberg
cells and their variants. In addition, abundant CD30- and
CD15- positive cells may be also helpful for differential
diagnosis with a large B-cell lymphoma. In parasitic or viral
infections, it would yield polypides, eggs, or viral inclusion
bodies under microscopy. Taken together, eosinophilic
granuloma, Hodgkin’s lymphoma and parasitic or viral
infections could be excluded respectively.
Based on the cellular, immunohistochemical and molecu-
lar findings, we think that this is a unique case of primary
pulmonary large B cell lymphoma with tissue eosinophilia.
The mechanism clarifying the relationship between tissue
eosinophilia and B cell lymphoma remains unknown. Typ-
ically, it is believed that the eosinophilia is caused by the
production of various cytokines, such as interleukin (IL)-5,
IL-3, and granulocyte–macrophage colony–stimulating
factor (GM-CSF) by B cell lymphoma cells or non-
neoplastic T lymphocytes activated by B cell lymphoma
cells [30,31]. In addition to the eosinophil chemotactic
factors IL-3 and GM-CSF, IL-5 is a major soluble factor
for mediating eosinophilia. It can be both a paracrine
secretion from T cells [32] and an autonomous autocrine
secretion from activated eosinophils [33,34]. Although the
role of IL-4 in eosinophil recruitment is controversial [31],
IL-4 is highly expressed by T cytotoxic 2 cells, with
abundant background eosinophils, in CD8+ lymphomatoid
papulosis [35]. Generally, these secreted cytokines may
either act locally, recruiting eosinophils to the neoplasm,
or have a systematic effect, increasing the number of
eosinophils maturing and leaving the bone marrow
[29]. Although the reason for tissue eosinophilia is as
yet unknown, a large study of 1511 diagnostic biopsy
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correlated strongly with poor prognosis in nodular scleros-
ing Hodgkin’s disease [36]. Similarly, the prognosis of large
B cell lymphoma with tissue eosinophilia remains unknown
for the rare of such cases and should also be considered.
There is evidence that MALT lymphoma of the lung is
a very indolent disease with the potential for spontaneous
regression [37] and that DLBCL of the lung may not
portend as poor a prognosis as in other extranodal sites
[11]. Prompt pathological diagnosis and initiation of
therapy, including surgery, chemotherapy, radiotherapy,
or combined treatments, are crucial to patient outcome. To
date, the most effective therapy is anthracycline-containing
chemotherapy, such as the CHOP or CHOP-like regimen,
which is more commonly offered. The long-term follow-up
study of Neri et al. showed that patients treated with CHOP
achieved complete response (CR) >80% and progression-
free survival (PFS) and overall survival (OS) >5 years [11].
Although the addition of rituximab to CHOP (R-CHOP)
increased the CR rate, PFS, and OS in DLBCL [38,39],
especially in younger patients with low clinical risk, a
recent study reported that there was no statistical differ-
ence in PPL-DLBCL following a retrospective comparison
of patients who received R-CHOP or CHOP alone [40].Conclusion
In conclusion, this is the first reported case of T- cell/
histiocyte-rich large B cell lymphoma with tissue eosino-
philia of the lung, which is difficult to diagnose and is easily
confused with other diseases. Given the low incidence and
favorable prognosis of PPL B cell lymphoma, a high index
of suspicion must be maintained and the diagnosis should
be performed with care using immunohistochemical stain-
ing; molecular analysis might aid the diagnosis, particularly
in the case of small specimens such as that obtained by
needle biopsy.Consent
Written informed consent was obtained from the
patient for publication of this Case Report and any
accompanying images.
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